Key Metrics of Bruker Corporation
Revenue$3.0B▲ 17.1% YoYFY 2023
Operating income$437M▲ 1.0% YoY
Net profit$429M▲ 43.6% YoY
Shareholders' equity$1.4B
Market cap$8.7BBRKR · $57.31
Competitors10identified
About Bruker Corporation
Sectors
Company details
- Listed
- Nasdaq: BRKR
Operational Areas of Bruker Corporation
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameBruker Corporation
TickerBRKR
ExchangeNasdaq
CountryUnited States
SEC CIK0001109354
Listed since—
IndustryBiotechnology: Laboratory Analytical Instruments
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
BRKR · Nasdaq · SEC CIK 0001109354
Last price · 23 Oct 2026
$57.31
−3.04%
Market cap$8.7B
P/E19.8On FY 2023 diluted EPS
Volume2,371,759
SectorIndustrialsBiotechnology: Laboratory Analytical Instruments
Country · IPOUnited States
BRKR share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Bruker Corporation
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.